Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Norihisa Ohishi"'
Autor:
Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo, Ghassan K. Abou-Alfa
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Se
Externí odkaz:
https://doaj.org/article/58e51e59a3e54e3985147d1bf44c110e
Autor:
Ghassan K. Abou-Alfa, Takehiko Kawanishi, Norihisa Ohishi, Mikiko Nakamura, Chao Xu, Ya-Chi Chen, Ruey-min Lee, Satofumi Iida, Toshihiko Ohtomo, Cheikh Diack
Publikováno v:
British Journal of Clinical Pharmacology. 84:944-951
Aims Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican-3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a63d9fac220809ff306179b3fa5845a1
https://doi.org/10.1111/bcp.13530
https://doi.org/10.1111/bcp.13530
Autor:
Norihisa Ohishi, Ghassan K. Abou-Alfa, Toshihiko Ohtomo, Neeta Pandit-Taskar, Serge K. Lyashchenko, Joseph A. O'Donoghue, Peter Smith-Jones, Volkan Beylergil, Steven M. Larson, Shutian Ruan, Jorge A. Carrasquillo
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-11 (2018)
EJNMMI Research
EJNMMI Research
Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b60c65915e517fde9a75deb46d0df0a
http://link.springer.com/article/10.1186/s13550-018-0374-8
http://link.springer.com/article/10.1186/s13550-018-0374-8
Autor:
Mikiko, Nakamura, Chao, Xu, Cheikh, Diack, Norihisa, Ohishi, Ruey-Min, Lee, Satofumi, Iida, Takehiko, Kawanishi, Toshihiko, Ohtomo, Ghassan K, Abou-Alfa, Ya-Chi, Chen
Publikováno v:
British journal of clinical pharmacology. 84(5)
AIMS: Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican‐3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::843124b866db4624a417477c60696099
https://pubmed.ncbi.nlm.nih.gov/29381229
https://pubmed.ncbi.nlm.nih.gov/29381229
Autor:
Takayoshi Tanaka, Toshihiko Ohtomo, Ghassan K. Abou-Alfa, Volkan Beylergil, Zhong Zhe Lin, Ya Chi Chen, Jennifer Ma, Joseph A. O'Donoghue, Catherine Frenette, Tamara Agajanov, Frederic Boisserie, Ray Lee, Ann-Lii Cheng, Norihisa Ohishi, Bert H. O'Neil, Lawrence H. Schwartz, Yu-Yun Shao, Steven M. Larson, Jorge A. Carrasquilo, Shutian Ruan, Serge K. Lyashchenko, Bolorsukh Gansukh, Hideo Morikawa, Chia Jui Yen, Chih-Hung Hsu, Peter Justin Wan, Yuko Maki, Laura Di Laurenzio, Neeta Pandit-Taskar, Peter Smith-Jones
Codrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC. A phase I study evaluated the combination with sorafenib in HCC. In a 3 + 3 design, codrituzumab was given intravenously in various doses with sorafenib 400 mg twice d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60257f3261ce85fe5726517b90bc4cd3
https://europepmc.org/articles/PMC5548107/
https://europepmc.org/articles/PMC5548107/
Autor:
Philip J. Gold, Thomas A. Abrams, Toshihiko Ohtomo, Philip A. Philip, Hideo Morikawa, Anthony B. El-Khoueiry, Andrew X. Zhu, Norihisa Ohishi
Publikováno v:
Clinical Cancer Research. 19:920-928
Purpose: GC33 is a novel recombinant fully humanized monoclonal antibody that binds to human glypican-3 (GPC3). The antitumor activity of GC33 was shown in preclinical models of hepatocellular carcinoma (HCC). This first-in-man clinical trial was con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d18b49f9f98836dd6c953256d68e055
https://doi.org/10.1158/1078-0432.ccr-12-2616
https://doi.org/10.1158/1078-0432.ccr-12-2616
Autor:
Elisabeth G.E. de Vries, Danique Giesen, Carolien P. Schröder, Stijn J.H. Waaijer, Marjolijn N. Lub-de Hooge, Athos Gianella-Borradori, Takahiro Ishiguro, Yuji Sano, Norihisa Ohishi
Publikováno v:
Cancer Research. 78:3028-3028
BACKGROUND: ERY974, a modified monoclonal IgG4 bispecific antibody directed against human CD3 on T cells and glypican 3 (GPC3) on tumor cell, is currently in phase I clinical trial. The oncofetal protein GPC3 is overexpressed in several tumor types.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83794c1244a684aa2edf8426304b895e
https://doi.org/10.1158/1538-7445.am2018-3028
https://doi.org/10.1158/1538-7445.am2018-3028
Publikováno v:
Drug Metabolism and Pharmacokinetics. 16:175-180
Eleven sulfur-containing conjugates were determined in the bile of rats administered with m-DCB. Mercapturic acid conjugate concentration in urine after administration of m-DCB to bile duct-cannulated rats was measured. 1. Follow ing administration o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53f64fd996342a7a87a3a47962c6f5a0
https://doi.org/10.2133/dmpk.16.175
https://doi.org/10.2133/dmpk.16.175
Autor:
Ken Okano, Norihisa Ohishi, Satofumi Iida, Tsuneo Okutomi, Masaki Ishigai, Akira Okazaki, Toshito Nakagawa, Masami Hayashi, Yoshihiko Ishitani
Publikováno v:
Drug Metabolism and Pharmacokinetics. 10:617-624
Transfer of radioactivity into fetus and milk were studied after a single oral administration of 14C-Q-35 at the dose of 20 mg/kg in pregnant and in lactating rats.1. Whole body autoradiography of pregnant rats showed that radioactivity distributed w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ed84b107ea6c3ecc09dc38f6418b35a
https://doi.org/10.2133/dmpk.10.617
https://doi.org/10.2133/dmpk.10.617
Publikováno v:
Xenobiotica. 24:873-880
1. The changes in the activity of drug-metabolizing enzymes and in the content of P450 isozymes in renal and hepatic microsomes after treatment of the male Sprague-Dawley rat with cis-diamminedichloroplatinum (Cisplatin, CDDP) were examined. 2. NADPH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d78ab9c962e1bca9a7a31c2c268d3c65
https://doi.org/10.3109/00498259409043286
https://doi.org/10.3109/00498259409043286